Melatonin acts synergistically with pazopanib against renal cell carcinoma cells through p38 mitogen-activated protein kinase-mediated mitochondrial and autophagic apoptosis

• Main Authors: Chien-Pin Lai (Author), Yong-Syuan Chen (Author), Tsung-Ho Ying (Author), Cheng-Yen Kao (Author), Hui-Ling Chiou (Author), Shao-Hsuan Kao (Author), Yi-Hsien Hsieh (Author)
• Format: Book
• Published: The Korean Society of Nephrology, 2023-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background Mounting evidence indicates that melatonin has possible activity against different tumors. Pazopanib is an anticancer drug used to treat renal cell carcinoma (RCC). This study tested the anticancer activity of melatonin combined with pazopanib on RCC cells and explored the underlying mech...